Biome Australia Group recently held its Jan 2024 Strategy Meeting, unveiling the Vision 27 Strategic Plan under Blair Norfolk's leadership. The company is focused on becoming a global leader in the complementary medicine industry with a three-year sales revenue target of up to $85m from FY25 to FY27. Key areas of focus include Distribution Growth and Business Development, International Market Acceptance and Growth, Supply Chain Improvement, and the Launch of a New Brand and Product Range.

While achieving cash flow and EBITDA positivity in the second half of FY24, Biome faces risks common to early-stage companies, such as market share acquisition and regulatory compliance challenges. To mitigate these risks and ensure sustainable growth, the company is prioritizing effective management, product development, international expansion, and regulatory compliance.

Biome encourages investors to engage with management for any inquiries or clarifications regarding the Vision 27 Strategic Plan. Contact CEO Blair Norfolk or CFO Douglas Loh via email at corporate@biomeaustralia.com or visit the websites biomeaustralia.com and activatedprobiotics.com.au for further information.